SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-23-009497
Filing Date
2023-06-09
Accepted
2023-06-09 14:41:05
Documents
2
Period of Report
2023-06-01

Document Format Files

Seq Description Document Type Size
1 form3-06092023_060602.html 3  
1 form3-06092023_060602.xml 3 1675
2 ex24-06092023_060603.htm EX-24 4816
  Complete submission text file 0001415889-23-009497.txt   7954
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 4995 BRADENTON AVE SUITE 240 DUBLIN OH 43017
Business Address
Stefanelli Jill (Reporting) CIK: 0001980919 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 231004891